KPV vs Larazotide

Before anything else: the dataset lists KPV and Larazotide in each other's stacks. They are run together more often than they are chosen between, so if you came here for a winner, the first honest answer is that this may not be an either/or.

Both are classed here as healing and repair compounds, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is gut health and inflammation. On this site's goal weighting — an editorial priority score, not a measure of effect size — KPV rates 5/5 for gut health and Larazotide rates 5/5. Outside that overlap only KPV goes further, carrying weight for skin and hair; Larazotide's declared goals stop at the overlap.

This is the part that decides most of it. Larazotide has controlled human trials behind it, without an approval — its phase 3 was stopped for futility at interim analysis. KPV has animal and cell data only, and no controlled human dosing trials — rodent colitis models and in-vitro work. That gap is the headline, and it is a statement about the literature rather than a promise about you: a compound with trial data can still do nothing for your case, and one without it is unproven rather than disproven.

KPV is a subcutaneous injection, taken by mouth, and applied to the skin; Larazotide is taken by mouth. Neither one forces you onto a needle.

No half-life is published for either compound in this dataset. That absence is itself information: it means the pharmacokinetics have not been characterized well enough to quote, so both dosing schedules — once daily for KPV, three times daily for Larazotide — are convention.

Committed time differs: KPV runs 8 weeks, Larazotide runs 12 weeks.

The contraindication lists are not the same: KPV flags active malignancy, which Larazotide does not; Larazotide flags under 18, which KPV does not. If any of those describe you they remove a compound from consideration outright, regardless of everything above.

KPV is rated beginner here and Larazotide intermediate. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.